According to the AAP guidelines adopted in Myanmar, where screening for G6PD is not performed on a routine basis, neonatal assessment including the Beutler fluorescent spot test should be performed when neonates develop hyperbilirubinemia {bilirubin concentrations greater than the 95th percentile [150 μmol/L (8.8mg/dL)]} within the first 24 h of life (6). The gene discussed is G6PD; the disease is Hyperbilirubinemia.